BRPI9811989B8 - uso do ácido 9-cis retinóico para a fabricação de um medicamento - Google Patents

uso do ácido 9-cis retinóico para a fabricação de um medicamento

Info

Publication number
BRPI9811989B8
BRPI9811989B8 BRPI9811989A BR9811989A BRPI9811989B8 BR PI9811989 B8 BRPI9811989 B8 BR PI9811989B8 BR PI9811989 A BRPI9811989 A BR PI9811989A BR 9811989 A BR9811989 A BR 9811989A BR PI9811989 B8 BRPI9811989 B8 BR PI9811989B8
Authority
BR
Brazil
Prior art keywords
pharmaceutically acceptable
retinoic acid
cis
drug
manufacture
Prior art date
Application number
BRPI9811989A
Other languages
English (en)
Portuguese (pt)
Other versions
BR9811989A (pt
BRPI9811989B1 (pt
Inventor
Ott Fritz
Bollag Werner
Original Assignee
Basilea Pharmaceutica Ag
Hoffmann La Roche
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8227266&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI9811989(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Basilea Pharmaceutica Ag, Hoffmann La Roche, Glaxo Group Ltd filed Critical Basilea Pharmaceutica Ag
Publication of BR9811989A publication Critical patent/BR9811989A/pt
Publication of BRPI9811989B1 publication Critical patent/BRPI9811989B1/pt
Publication of BRPI9811989B8 publication Critical patent/BRPI9811989B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI9811989A 1997-08-23 1998-08-18 uso do ácido 9-cis retinóico para a fabricação de um medicamento BRPI9811989B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97114651A EP0908179A1 (en) 1997-08-23 1997-08-23 Treatment of cell-mediated immune diseases
PCT/EP1998/005236 WO1999009969A1 (en) 1997-08-23 1998-08-18 Treatment of cell-mediated immune diseases

Publications (3)

Publication Number Publication Date
BR9811989A BR9811989A (pt) 2000-09-05
BRPI9811989B1 BRPI9811989B1 (pt) 2015-12-15
BRPI9811989B8 true BRPI9811989B8 (pt) 2021-05-25

Family

ID=8227266

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9811989A BRPI9811989B8 (pt) 1997-08-23 1998-08-18 uso do ácido 9-cis retinóico para a fabricação de um medicamento

Country Status (18)

Country Link
US (2) US6589989B1 (https=)
EP (2) EP0908179A1 (https=)
JP (1) JP3522220B2 (https=)
KR (1) KR100596260B1 (https=)
CN (1) CN1136845C (https=)
AT (1) ATE259224T1 (https=)
AU (1) AU739440B2 (https=)
BR (1) BRPI9811989B8 (https=)
CA (1) CA2301907C (https=)
DE (1) DE69821624T2 (https=)
DK (1) DK1007020T3 (https=)
ES (1) ES2214729T3 (https=)
NO (1) NO327141B1 (https=)
NZ (1) NZ502812A (https=)
PT (1) PT1007020E (https=)
RU (1) RU2238083C2 (https=)
TR (1) TR200000488T2 (https=)
WO (1) WO1999009969A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541469B2 (en) * 1997-08-23 2013-09-24 Glaxo Group Limited Treatment of cell-mediated immune diseases
US20020031539A1 (en) * 2000-08-30 2002-03-14 The Brigham And Women's Hospital, Inc. Oxidized forms of retinoic acid as ligands for peroxisome proliferator activated receptor gamma
DE10255861A1 (de) * 2002-11-29 2004-06-17 Axxima Pharmaceuticals Ag Gegen Hepatitis C-Virusinfektionen nützliche Verbindungen und Substanzen
FR2834216B1 (fr) * 2001-12-27 2004-04-30 Pharmascience Lab Composition cosmetique ou pharmaceutique comprenant au moins une oxazoline pour inhiber la migration des cellules de langerhans, et ses utilisations
JP2004020220A (ja) * 2002-06-12 2004-01-22 Pioneer Electronic Corp 通信システム及び方法、通信端末装置、通信センタ装置、並びにコンピュータプログラム
TW579640B (en) * 2002-10-23 2004-03-11 Veutron Corp Light gathering device of scanner
EP1527774A1 (en) * 2003-11-03 2005-05-04 Basilea Pharmaceutica AG New formulation for retinoid-containing soft gelatin capsules
EP3326623A1 (en) * 2003-03-14 2018-05-30 University of Washington Retinoid replacements and opsin agonists and methods for the use thereof
PL1615879T3 (pl) 2003-04-11 2015-02-27 Glaxo Group Ltd Sposób wytwarzania kwasu 9-cis-retinowego
US7122751B1 (en) * 2004-01-16 2006-10-17 Cobalt Flux Switch apparatus
CN1921843A (zh) * 2004-01-23 2007-02-28 独立行政法人科学技术振兴机构 含视黄酸的糖尿病治疗药
NZ587006A (en) * 2004-06-18 2011-12-22 Univ Washington 11-cis-Retinal derivatives and methods for the use thereof for the treatment of visual disorders
AU2012216808B2 (en) * 2004-06-18 2015-04-30 University Of Washington Retinal derivatives and methods for the use thereof for the treatment of visual disorders
AU2015207903B2 (en) * 2004-06-18 2017-08-17 University Of Washington Retinal derivatives and methods for the use thereof for the treatment of visual disorders
WO2007029760A1 (ja) * 2005-09-09 2007-03-15 R & R Inc. 腸疾患の予防及び／又は治療のための医薬
WO2009102418A1 (en) 2008-02-11 2009-08-20 University Of Washington Methods for the treatment and prevention of age-related retinal dysfunction
US8580278B2 (en) * 2009-06-03 2013-11-12 Trustees Of Dartmouth College Nutraceutical composition and methods for preventing or treating multiple sclerosis
CN102612375B (zh) 2009-09-15 2016-01-27 Qlt股份有限公司 含有在脂质媒介物中的9-顺式-视黄酯的药物制剂
WO2011056561A1 (en) 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Methods and compositions for the generation and use of conformation-specific antibodies
CN107308143A (zh) 2010-04-19 2017-11-03 诺维利昂治疗股份有限公司 用于治疗或改善与内源性类视黄醇缺乏有关的视觉障碍的治疗方案和方法
WO2012125724A1 (en) 2011-03-14 2012-09-20 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of proliferative disorders
US10487114B2 (en) 2011-04-27 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
CN102247348A (zh) * 2011-05-23 2011-11-23 天津拓飞生物科技有限公司 9-顺式维甲酸在制备治疗糖尿病皮肤溃疡的药物中的应用
WO2012162698A1 (en) * 2011-05-26 2012-11-29 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the treatment of immune disorders
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
JP6576636B2 (ja) 2012-03-01 2019-09-18 ノベリオン セラピューティクス インコーポレイテッド 内因性レチノイド欠乏に関連する視覚障害における視覚機能を改善するための治療的計画および方法
WO2013185055A1 (en) 2012-06-07 2013-12-12 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of pin1
US9221854B2 (en) 2012-08-17 2015-12-29 Basf Se Isomerization of olefinic compounds
WO2014026896A1 (de) 2012-08-17 2014-02-20 Basf Se Isomerisierung olefinischer verbindungen
US20150202172A1 (en) * 2014-01-22 2015-07-23 Glaxo Group Limited Novel method of use
WO2016011268A1 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Atra for modulating pin1 activity and stability
WO2016011265A2 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Biomarkers for pin1-associated disorders
US10548864B2 (en) 2015-03-12 2020-02-04 Beth Israel Deaconess Medical Center, Inc. Enhanced ATRA-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
JP6918365B2 (ja) 2015-08-19 2021-08-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 脂質化ｐｓａ組成物および方法
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use
CN113499335B (zh) * 2021-07-13 2023-06-20 中国人民解放军军事科学院军事医学研究院 一种靶向自噬融合治疗神经退行性疾病的药物
WO2025108208A1 (zh) * 2023-11-21 2025-05-30 南京纽邦生物科技有限公司 用于改善或维持皮肤、毛囊、头皮或毛发健康的方法和组合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525635A (en) * 1986-02-04 1996-06-11 Moberg; Sven Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof
US5093360A (en) * 1989-04-07 1992-03-03 Yu Ruey J Retinal, derivatives and their therapeutic use
US5057501A (en) * 1990-03-13 1991-10-15 Dermatologic Research Corporation Methods for treatment of papulosquamous and eczematous diseases
US5932622A (en) * 1991-12-18 1999-08-03 The Salk Institute For Biological Studies Method for in vivo modulation of non-malignant skin-related processes with 9-cis-retinoic acid
KR100274101B1 (ko) 1992-01-22 2000-12-15 프리돌린 클라우스너, 롤란드 비. 보레르 9-시스 레틴산을 함유하는 약제학적 조성물
US5750570A (en) * 1992-03-31 1998-05-12 The Regents Of The University Of Michigan Method of treatment of hyperpigmentation in black skin with retinoic acid and method of lightening black skin with retinoic acid
CA2093577C (en) 1992-05-07 2006-01-03 Michael Klaus Alkyl or alkoxy substituted s-heterocyclic retinoids
TW272187B (https=) * 1992-05-20 1996-03-11 Hoffmann La Roche
WO1994022818A1 (en) * 1993-04-05 1994-10-13 Pfizer Inc. Method for the preparation of 9-cis retinoic acid
US5457129A (en) * 1993-05-17 1995-10-10 Research Development Foundation Inhibition of nitric oxide production by retinoic acid
FR2717686B1 (fr) * 1994-03-22 1996-06-28 Fabre Pierre Cosmetique Composition dermo-cosmétologique et procédé de préparation.
DE4415204A1 (de) * 1994-04-30 1995-11-02 Carl Heinrich Dr Weischer Neue Retinol (Vitamin A) -Derivate, deren Herstellung und Verwendung als Arzneimittel und Kosmetika
FR2728790B1 (fr) * 1994-12-29 1997-01-24 Cird Galderma Composition modulant l'apoptose comprenant du methonial ou tout facteur influencant le taux intracellulaire de methonial
US5721103A (en) * 1994-12-30 1998-02-24 Ligand Pharmaceuticals Incorporated Trienoic retinoid compounds and methods
US5837728A (en) * 1995-01-27 1998-11-17 Molecular Design International 9-cis retinoic acid esters and amides and uses thereof
FR2735367B1 (fr) * 1995-06-19 1997-07-18 Cird Galderma Utilisation de ligands specifiques des recepteurs rxrs
FR2752734B1 (fr) * 1996-09-02 1998-11-06 Cird Galderma Utilisation de retinoides pour la preparation d'un medicament destine a traiter les affections liees a une surexpression de vegf
US5994081A (en) * 1998-04-27 1999-11-30 Incyte Pharamaceuticals, Inc. Human keratins
US20030105031A1 (en) * 2001-11-06 2003-06-05 Rosenbloom Richard A. Methods for the treatment of skin disorders

Also Published As

Publication number Publication date
DK1007020T3 (da) 2004-06-07
DE69821624T2 (de) 2004-09-23
KR100596260B1 (ko) 2006-07-03
JP2003526595A (ja) 2003-09-09
JP3522220B2 (ja) 2004-04-26
ES2214729T3 (es) 2004-09-16
EP1007020A1 (en) 2000-06-14
TR200000488T2 (tr) 2000-07-21
WO1999009969A1 (en) 1999-03-04
NO20000870D0 (no) 2000-02-22
PT1007020E (pt) 2004-05-31
CA2301907C (en) 2009-02-10
CN1268886A (zh) 2000-10-04
DE69821624D1 (de) 2004-03-18
NZ502812A (en) 2002-05-31
US6589989B1 (en) 2003-07-08
US20040039056A1 (en) 2004-02-26
NO327141B1 (no) 2009-05-04
CA2301907A1 (en) 1999-03-04
EP0908179A1 (en) 1999-04-14
BR9811989A (pt) 2000-09-05
AU9435698A (en) 1999-03-16
RU2238083C2 (ru) 2004-10-20
KR20010023186A (ko) 2001-03-26
EP1007020B1 (en) 2004-02-11
CN1136845C (zh) 2004-02-04
ATE259224T1 (de) 2004-02-15
AU739440B2 (en) 2001-10-11
NO20000870L (no) 2000-02-22
BRPI9811989B1 (pt) 2015-12-15

Similar Documents

Publication Publication Date Title
BRPI9811989B8 (pt) uso do ácido 9-cis retinóico para a fabricação de um medicamento
ATE130758T1 (de) Arzneimittel zur intranasalen verabreichung, die ketorolac r enthalten.
NO174412C (no) Fremgangsmåte for fremstilling av en farmasöytisk formulering med programmert frigjöring for oral anvendelse
NO920740D0 (no) Doseringsform for oral administrering av hypoglykemisk glipizid
DE60334692D1 (de) Ophthalmologische zubereitung enthaltend roflumilast in der behandlung von krankheiten der augen
JP2023116449A (ja) 体表面の障害の処置のためのデバイスおよび方法
RU2486898C2 (ru) Составы с сангвинарином, хелеритрином или хелидонином для лечения бородавок, папиллом и псориатических бляшек
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
ATE420624T1 (de) Pharmazeutische zusammensetzungen zurbehandlung von augenerkrankungen
ES2147788T3 (es) 3,4-diarilcromanos para el tratamiento de la dermatitis.
KR910005858A (ko) 지방산 요법
JPH04243825A (ja) 色素沈着症治療剤
EP0294914A3 (en) Nedocromil for the treatment of dermatological disorders
CA2474703A1 (en) Therapeutic agent of glaucoma comprising bunazosin and prostaglandins
US4218445A (en) N,N'Dibenzylethylenediamine-diacetylsalicylate, a novel chemotherapeutic agent for pain relief by external application
GEP20012366B (en) Thienyl-, Furil-, Pyrrolyl- and Biphenyl-Sulfonamides, Their Derivatives, Their Use in Medicinal Purposes, Pharmaceutical Composition Containing the Same and Method for Treatment
ATE181828T1 (de) Oral anzuwendendes arzneimittel bestehend aus ibuprofen
KR910015299A (ko) 우울증 치료방법

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: BASILEA PHARMACEUTICA AG (CH)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: A61K 31/07, A61P 37/02, C07C 403/20

Ipc: A61K 31/07 (2008.01), A61P 37/02 (2008.01), C07C 4

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: REFERENTE A RPI 1932 DE 15/01/2008.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: REFERENTE A RPI 1970 DE 07/10/2008.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA ( ART. 8O COMBINADO COM ART. 13 DA LPI ), NAO APRESENTA SUFICIENCIA DESCRITIVA ( ART. 24 DA LPI )

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25A Requested transfer of rights approved

Owner name: GLAXO GROUP LIMITED (GB)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/12/2015, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/08/1998 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 18/08/2018